The European Chemicals Agency (ECHA) urges a broad ban on PFAS due to significant environmental and health risks, including potential impacts on the liver, immune system, fertility, and cancer risk, with targeted exemptions only where alternatives are lacking.

An expert European report backs a wide restriction of PFAS across the EU, allowing exemptions for strategic sectors such as medicine if no viable alternatives exist.

RAC and SEAC differ in approach but both push for strong PFAS action: a total ban with minimal exemptions or a broad ban with carefully managed exemptions and sector-specific plans.

Lobbying and regulatory negotiations are ongoing between industry groups and environmental organizations as debates over feasibility and impact continue.

Exemptions may be allowed for certain uses if alternatives are unavailable and socio-economic costs justify it, though there is uncertainty about whether proposed risk-management measures are adequate.

A 60-day public consultation has begun, inviting input from industry, NGOs, researchers, and the public, and will run through late May, with a final joint opinion due by year-end guiding a Commission proposal.

The consultation is open until May 25, after which the European Commission will draft a legislative proposal based on the assessments and ensuing joint opinions.

15k

Internal disagreements at ECHA center on how sweeping the ban should be: a total ban is seen as most effective but potentially disproportionate without substitutes, while exemptions and sector plans are viewed as more balanced.

Final decisions hinge on formalizing economic-impact guidance and subsequent EU Commission proposals before legislation is drafted.

The economic impact assessment is still being formalized, with conclusions pending before the Commission can draft the legislative proposal.

ECHA currently views existing rules as insufficient, backing a comprehensive ban while acknowledging that exemptions may be necessary where no alternatives exist.